177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
Part of paid clinical trials in Dothan, Alabama.
- Sponsor
- Radiopharm Theranostics, Ltd
- Study ID
- NCT07189871
- Phase
- PHASE1/PHASE2
- Status
- Recruiting
Conditions
- Castration-Resistant Prostate Cancer (CRPC)
- Cervical Cancer
- Colorectal Cancer
- Endometrial Cancer
- Esophageal Squamous Cell Carcinoma (ESCC)
- Head &Amp; Neck Squamous Cell Carcinoma (HNSCC)
- NSCLC (Non-small Cell Lung Cancer)
- Ovarian Cancer
- Small Cell Lung Cancer (SCLC )
- TNBC, Triple Negative Breast Cancer
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- 177Lu-BetaBart — DRUGBetaBart administered by intravenous (IV) infusion every 6 weeks
Study Details
A Phase 1/2a Dose Escalation and Expansion Study of the Safety, Tolerability, and Preliminary Clinical Activity of 177LuBetaBart, a 177Lu-Labeled Anti-B7-H3 Monoclonal Antibody, in Patients with Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
Key Dates
- Start date
- Feb 23, 2026
- Status verified
- Mar 2026
- Primary completion
- Dec 31, 2027
- Completion
- Dec 31, 2027
Study Design
- Enrollment
- 61 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: 177 Lu-BetaBart - Dose escalation and Phase 2a expansionDose escalation and treatment and imaging period
Primary Outcome Measure
Recommended dose(s) of 177Lu-BetaBart for future exploration (phase 1) [ Time Frame: 6 weeks ]
Central Contacts
- Dimitris Voliotis, MD646-535-5017
Locations (4)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Dothan Hematology & Oncology | Dothan | Alabama | 36303 | |
| BAMF Health | Grand Rapids | Michigan | 49503 | |
| Nebraska Cancer Specialists | Omaha | Nebraska | 68130 | |
| XCancer | Omaha | Nebraska | 68130 |
Find similar trials in Dothan, AL
Related Studies
- Integrated Cancer Repository for Cancer ResearchRecruiting · University of Nebraska · Greenwood Village, Colorado
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryRecruiting · Massive Bio, Inc. · Birmingham, Alabama
- The DETECT Study: Discovery and Evaluation of Testing for Endometrial and Ovarian Cancer in TamponsRecruiting · University of Alabama at Birmingham · Birmingham, Alabama
- Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) CancersPHASE1/PHASE2 · Recruiting · Regeneron Pharmaceuticals · Birmingham, Alabama